1418107
type: Document
created: 2026-07-31T21:11:39.312Z
modified: 2026-07-31T21:11:39.312Z
doi: 10.1016/j.cgh.2026.01.017
title: Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis.
related by: Authorship
  type: Relationship
arg_2000028:
  has URL:
    type: URL
    url: http://doi.org/10.1016/j.cgh.2026.01.017
  type: Individual
  arg_2000029: 1418107
type: AcademicArticle
issued: 2026-01-28
has publication venue:
  type: Collection
  title: Clinical Gastroenterology and Hepatology
  publication venue for: 1418107